La chaîne d'options affiche les données clés des options sur actions de ARM Holdings à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour ARM Holdings..

ARM Holdings (NASDAQ:ARM) Stock, Chaîne d'Options

ARM Holdings

Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.

Arm Holdings plc - American Depositary Shares

ARM Holdings PLC

Un Monde International Worldwide Ltd

ARMOR ELECTRIC INC by Armor Electric, Inc.

Armor Electric Inc

Aramark

Current Energy and Renewables Corp

Aris Mining Corp

ARMOR

ARMO BIOSCIENCES ORD

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals Inc

Exchange Listed Funds Trust Armor US Equity Index ETF

GLOBAL X ETFS ICAV ETF

Arma Services Inc

Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) reported better-than-expected results for its <a href="https://www.benzinga.com/quote/PNR/earnings">third quarter on Tuesday</a>.
The company reported that third-quarter 2024 net sales fell 2% year over year to $993 million, beating the consensus of $988.8 million. Adjusted EPS rose 16% Y/Y to $1.09, surpassing the consensus of $1.07.
For FY24 Outlook, Pentair raised adjusted EPS to $4.27 (from $4.25) vs. consensus of $4.25. Meanwhile, the company continues to see sales growth of roughly flat to down 1% on a reported basis.
Pentair sees fourth-quarter adjusted EPS of $1.02 versus a consensus of $1.02 and sales of around $965 million-$975 million vs. a consensus of $989.2 million.
CEO John L. Stauch said, &#8220;Our relentless dedication to strong execution, Transformation, and delivering value to our customers has driven yet another quarter of significant free cash flow and outstanding results, surpassing our expectations. Our balanced approach across our water portfolio continues to validate the effectiveness of our strategy. We have made substantial progress on 80/20 with the completion of training on a majority of our total revenue."
Pentair shares fell 1.3% to trade at $97.04 on Wednesday.
These analysts made changes to their price targets on Pentair following earnings announcement.
<ul>
<li>Barclays analyst Julian Mitchell maintained Pentair with an Overweight and raised the price target from $105 to $108.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a462c943eaaa0001e788d5/jeffrey-hammond">Keybanc analyst Jeffrey Hammond</a> maintained the stock with an Overweight and raised the price target from $110 to $115.</li>
<li>Goldman Sachs analyst Brian Lee maintained Pentair with a Neutral and raised the price target from $93 to $103.</li>
<li>UBS analyst Damian Karas maintained the stock with a Buy and raised the price target from $100 to $115.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730078/stephen-tusa">JP Morgan analyst Stephen Tusa</a> maintained Pentair with a Neutral and raised the price target from $106 to $110.</li>
<li>TD Cowen analyst Joseph Giordano maintained the stock with a Buy and boosted the price target from $95 to $110.</li>
</ul>
Considering buying PNR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23142351/image-221-1024x494.png" alt="" class="wp-image-610472" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23142351/image-221-1024x494.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23142351/image-221-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23142351/image-221-768x371.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23142351/image-221.png 1197w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41488681/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Pentair Analysts Increase Their Forecasts Following Better-Than-Expected Q3 Results

WIIM

NVDA

Nvidia shares are trading lower Wednesday after CEO Jensen Huang reportedly acknowledged that Taiwan Semiconductor assisted in resolving a design flaw in its latest Blackwell AI chips.

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could soar to $200,000 by the end of 2025, driven by a combination of rising institutional demand and supply reduction following <a href="https://www.benzinga.com/money/what-is-bitcoin-halving">the latest halving</a>.
What Happened: In their October &#8220;Bitcoin Investing Guide,&#8221; Bernstein analysts highlighted Bitcoin's unique supply structure, particularly its capped total supply of 21 million coins and the halving events that reduce the rate at which new coins are created. These events occur every four years and effectively reduce the selling pressure from miners.
"After each halving cycle, the miners' rewards halve, which means half the miner sell pressure in the market," the report noted.
A major factor in this cycle is the introduction of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41487660/bitcoin-spot-etf-nets-79m-outflow-after-7-day-inflow-streak">spot Bitcoin ETFs</a>, which launched in January 2024. By September 2024, these ETFs had already accumulated $60 billion in assets under management, with Bernstein predicting this number could grow to $190 billion by the end of 2025.
<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40916462/michael-saylor-bitcoin-to-hit-13m-by-2045-will-get-us-to-a-different-place">Institutional adoption</a> is expected to play a pivotal role in Bitcoin's growth, with these ETFs providing access to traditional capital markets. While 80% of current ETF flows come <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40773784/bitcoin-etfs-are-not-an-adoption-vehicle-with-holders-on-2b-unrealized-losses-analyst-says">from retail investors</a>, Bernstein expects institutional participation to rise significantly.
According to a recent <a href="https://x.com/ki_young_ju/status/1848689728423661875">tweet</a> by CryptoQuant's founder, U.S. institutional ownership of spot Bitcoin ETFs is around 20%, with asset managers collectively holding 193,000 BTC.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/digital-assets"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41453688/bitcoin-dips-below-67-000-watch-these-key-support-levels-says-analyst">Bitcoin Dips Below $67,000: Watch These Key Support Levels, Says Analyst</a>
Why It Matters: Bernstein's model, based on a multiple of the marginal cost of production, suggests Bitcoin could rise to $500,000 by 2029 and potentially $1 million by 2033. For the 2025 target, the report estimates Bitcoin could reach 1.5 times its marginal production cost, leading to a projected price of $200,000—about three times its current value.
The analysts highlighted the &#8220;accumulate phase,&#8221; during which long-term holders buy up Bitcoin and surviving miners add capacity. Given Bitcoin&#8217;s status as a relatively new asset class, it has substantial room for growth compared to traditional financial assets.
Bernstein predicts that by 2025, Bitcoin ETFs could control 7% of the circulating supply, with this number potentially rising to 15% by 2033, up from the current 4.5%
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41480990/gary-gensler-wishes-happy-sweet-sixteen-to-bitcoin-ahead-of-whitepaper-anniversary-sec-cha">Gary Gensler Wishes &#8216;Happy Sweet Sixteen&#8217; To Bitcoin Ahead Of Whitepaper Anniversary — SEC Chair Says Decentralized Tech Compatible With Securities Law, But…</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Could Hit $200,000 By 2025, Driven By Institutional Demand and ETFs: Bernstein

JP Morgan analyst Ryan Brinkman maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Overweight and raises the price target from $64 to $70.

JP Morgan Maintains Overweight on General Motors, Raises Price Target to $70

TD Cowen analyst Bryan Bergin maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy and raises the price target from $200 to $230.

TD Cowen Maintains Buy on Fiserv, Raises Price Target to $230

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $310 to $315.

TD Cowen Maintains Buy on Danaher, Raises Price Target to $315

JP Morgan analyst Jay Kwon downgrades LG Display Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) from Overweight to Neutral.

Downgrades

JP Morgan Downgrades LG Display Co to Neutral

Jefferies analyst Brian Tanquilut maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Hold and lowers the price target from $19 to $9.

Jefferies Maintains Hold on Walgreens Boots Alliance, Lowers Price Target to $9

TD Cowen analyst Charles Rhyee maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Buy and lowers the price target from $413 to $372.

MEDP

TD Cowen Maintains Buy on Medpace Hldgs, Lowers Price Target to $372

Financial giants have made a conspicuous bullish move on ServiceNow. Our analysis of options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) revealed 38 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $394,047, and 30 were calls, valued at $2,480,134.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $520.0 and $1000.0 for ServiceNow, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of ServiceNow stands at 150.58, with a total volume reaching 1,748.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $520.0 to $1000.0, throughout the last 30 days.
<h3>ServiceNow Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729707342_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$193.0</td>
<td>$184.1</td>
<td>$187.25</td>
<td>$860.00</td>
<td>$936.2K</td>
<td style="text-align: right;">25</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$33.8</td>
<td>$30.6</td>
<td>$32.0</td>
<td>$1000.00</td>
<td>$153.6K</td>
<td style="text-align: right;">289</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$37.8</td>
<td>$37.0</td>
<td>$37.0</td>
<td>$950.00</td>
<td>$148.0K</td>
<td style="text-align: right;">127</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$22.7</td>
<td>$21.0</td>
<td>$21.4</td>
<td>$890.00</td>
<td>$102.7K</td>
<td style="text-align: right;">78</td>
<td style="text-align: right;">68</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$27.0</td>
<td>$25.5</td>
<td>$27.0</td>
<td>$910.00</td>
<td>$91.8K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">43</td>
</tr>
</tbody>
</table>

<h3>About ServiceNow</h3>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
In light of the recent options history for ServiceNow, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is ServiceNow Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 738,362, with NOW's price down by -1.48%, positioned at $904.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for ServiceNow</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $987.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $960. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on ServiceNow, which currently sits at a price target of $1025. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on ServiceNow, which currently sits at a price target of $950. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for ServiceNow, targeting a price of $980. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on ServiceNow, which currently sits at a price target of $1020. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ServiceNow options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on ServiceNow: Analyzing the Surge in Options Activity

On Tuesday, DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) announced progress in its regulatory efforts for the Viaskin Peanut patch, aimed at treating peanut allergies in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41467627/dbv-announces-positive-regulatory-updates-for-the-viaskin-peanut-patch-in-the-united-states-and-eu" rel="noreferrer noopener">toddlers and children</a>.
The company has aligned with the FDA under the Accelerated Approval Program for toddlers aged 1–3.
DBV has agreed to the FDA&#8217;s guidance on key study components required for approval, including the COMFORT Toddlers safety study, which must be completed before the US marketing application submission, and a confirmatory study to demonstrate the patch&#8217;s effectiveness.
DBV plans to begin enrolling subjects in the COMFORT Toddlers study in the second quarter of 2025, with <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33487292/dbv-technologies-advances-peanut-allergy-program-with-fda-support-on-pediatric-studies" rel="noreferrer noopener">around 300–350 toddlers</a>.
DBV has also made headway on the Viaskin Peanut patch for older children. In September 2024, the company completed patient screening for the Phase 3 VITESSE trial, enrolling 654 children aged 4–7 years. Topline data are expected in the fourth quarter of 2025.
Discussions between DBV and the FDA have also addressed the patch&#8217;s adhesion issues. The company proposed a labeling solution that links adhesion data to the patch&#8217;s efficacy and safety.
DBV also received scientific advice from the European Medicines Agency for a broader age range of 1–7 years in Europe.
In Europe, DBV has received scientific advice confirming that the EPITOPE study in 1–3-year-olds and positive results from the VITESSE study could support the European marketing application for the 1–7-year-old age group.
The company is planning a new safety study for toddlers with the modified patch to meet European requirements.
Despite its clinical progress, DBV&#8217;s financial situation raises concerns. The company reported cash and cash equivalents of $46.4 million as of September 30, 2024, and anticipates that this will fund operations only through the first quarter of 2025.
With ongoing operating losses, DBV has expressed uncertainty about its ability to continue operations without securing additional funding. The company is actively seeking new capital to support its research and potential product launch.
Price Action: DBVT stock is up 44.3% at $1.02 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation" target="_blank" rel="noreferrer noopener">Boeing Q3 Earnings: Revenue And Profit Decline, Cultural Challenges, CEO Ortberg Vows Transformation</a>.</li>
</ul>

Health Care

Movers

General

DBVT

Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway

Investors with a lot of money to spend have taken a bearish stance on Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Mastercard.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $161,337, and 10 are calls, for a total amount of $541,947.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $540.0 for Mastercard, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Mastercard's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Mastercard's whale activity within a strike price range from $380.0 to $540.0 in the last 30 days. 
<h3>Mastercard 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729707336_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$66.7</td>
<td>$64.6</td>
<td>$66.0</td>
<td>$450.00</td>
<td>$151.8K</td>
<td style="text-align: right;">107</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$28.5</td>
<td>$27.75</td>
<td>$27.75</td>
<td>$540.00</td>
<td>$135.9K</td>
<td style="text-align: right;">492</td>
<td style="text-align: right;">103</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$530.00</td>
<td>$52.2K</td>
<td style="text-align: right;">85</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>MA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.2</td>
<td>$20.75</td>
<td>$21.05</td>
<td>$525.00</td>
<td>$50.7K</td>
<td style="text-align: right;">78</td>
<td style="text-align: right;">24</td>
</tr>
<tr>
<td>MA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.2</td>
<td>$20.75</td>
<td>$21.05</td>
<td>$525.00</td>
<td>$48.4K</td>
<td style="text-align: right;">78</td>
<td style="text-align: right;">47</td>
</tr>
</tbody>
</table>

<h3>About Mastercard</h3>
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
Following our analysis of the options activities associated with Mastercard, we pivot to a closer look at the company's own performance.
<h3>Mastercard's Current Market Status</h3>
<ul>
<li>With a volume of 693,191, the price of MA is up 0.08% at $513.43. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mastercard</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $581.3333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Mastercard, maintaining a target price of $593. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Mastercard, which currently sits at a price target of $576. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Mastercard, which currently sits at a price target of $575. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Mastercard options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on Mastercard Options

Jefferies analyst Randal Konik maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Buy and raises the price target from $115 to $150.

Jefferies Maintains Buy on SharkNinja, Raises Price Target to $150

Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer.
Looking at options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $215,253 and 4, calls, for a total amount of $110,938.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $23.0 to $32.0 for Pfizer over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Pfizer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $23.0 to $32.0 in the last 30 days. 
<h3>Pfizer Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729707330_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.85</td>
<td>$0.83</td>
<td>$0.83</td>
<td>$28.00</td>
<td>$76.2K</td>
<td>23.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$0.35</td>
<td>$0.28</td>
<td>$0.28</td>
<td>$29.00</td>
<td>$35.4K</td>
<td>6.8K</td>
<td>550</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$32.00</td>
<td>$34.5K</td>
<td>339</td>
<td>320</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$32.00</td>
<td>$34.5K</td>
<td>339</td>
<td>220</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$32.00</td>
<td>$34.5K</td>
<td>339</td>
<td>120</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Having examined the options trading patterns of Pfizer, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 13,273,870, with PFE's price down by -0.12%, positioned at $28.8.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Pfizer</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $40.666666666666664.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $32. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at Pfizer's Options Market Dynamics

TD Cowen analyst Moshe Orenbuch maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Hold and raises the price target from $85 to $96.

ENVA

TD Cowen Maintains Hold on Enova International, Raises Price Target to $96

Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) reported better-than-expected second-quarter FY25 results on Tuesday.
Revenue rose 6% (both reported and constant currencies) to $1.116 billion, marginally exceeding the consensus of $1.11 billion. Adjusted EPS of $1.20 beat the consensus of $0.99.
The company raised its FY25 sales outlook to $4.39 billion -$4.47 billion, up 2% – 4% (from the previously expected $4.34 billion – $4.43 billion) versus the consensus of $4.512 billion. Logitech now sees an adjusted operating income of $720 million – $750 million (versus $700 million – $730 million prior view).
Hanneke Faber, chief executive officer, said, "Growth was broad-based, across regions, categories, and both our consumer and business customers. We launched a terrific set of innovations in the quarter and we are ready for the holidays."
Logitech shares fell 4.4% to trade at $80.26 on Wednesday.
These analysts made changes to their price targets on Logitech following earnings announcement.
<ul>
<li>Barclays analyst Tim Long maintained Logitech International with an Overweight and lowered the price target from $105 to $103.</li>
<li>JP Morgan analyst Samik Chatterjee maintained the stock with a Neutral and lowered the price target from $98 to $93.</li>
<li>Wedbush analyst Alicia Reese reiterated Logitech International with a Neutral and maintained a price target of $88.</li>
</ul>
Considering buying LOGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23141018/image-220-1024x529.png" alt="" class="wp-image-610437" style="width:718px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23141018/image-220-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23141018/image-220-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23141018/image-220-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23141018/image-220.png 1211w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41488681/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>

LOGI

Logitech International Analysts Slash Their Forecasts Following Q2 Results

TD Cowen analyst Cai von Rumohr maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy and raises the price target from $560 to $610.

TD Cowen Maintains Buy on Lockheed Martin, Raises Price Target to $610

<a href="https://www.benzinga.com/topic/jim-cramer">Jim Cramer is</a> once again ringing the bell for Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) fans. On CNBC's &#8220;Mad Money,&#8221; the fiery host recommended holding on to the AI stock, saying, &#8220;There is no level that the buyers won't take this stock higher.&#8221;
But while Cramer is urging investors to ride the momentum, let's dive into what the charts tell us ahead of Palantir's third-quarter earnings.
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23122444/Screenshot-2024-10-23-at-9.54.12-PM.png" alt="" class="wp-image-610185" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23122444/Screenshot-2024-10-23-at-9.54.12-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/23122444/Screenshot-2024-10-23-at-9.54.12-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h1 class="wp-block-heading">Bullish Wave Continues — But Beware the Overbought Zone</h1>
Palantir stock has been on an absolute tear this year, up a staggering 158% year-to-date. From a technical standpoint, the stock is basking in bullish glory, sitting comfortably above its five-, 20- and 50-day moving averages. The current price of $42.70 spells bullish across key indicators such as the eight-day SMA ($42.63) and the 20-day SMA ($40.80).
With a Moving Average Convergence/Divergence (MACD) of 2.02, the momentum favors the bulls. The stock's Relative Strength Index (RSI) at 67.56 is inching toward overbought territory, suggesting some caution is warranted.
Read Also: <a href="https://www.benzinga.com/top-stories/24/10/41486894/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a>
While Cramer may be encouraging investors to hold on and enjoy the ride, technicals hint that Palantir could be due for a breather.
<h1 class="wp-block-heading">Q3 Earnings on the Horizon: Will AI Hype Keep the Stock Climbing?</h1>
With the third quarter earnings less than two weeks away (on Nov. 4), Palantir's AI-powered momentum could continue driving investor excitement.
But, as the RSI suggests, this rocket ride may face turbulence soon.
For now, Palantir stock has bullish chart signals, but investors should keep one eye on the stock&#8217;s overbought status as it heads into earnings.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/10/41488713/tesla-stock-faces-selling-pressure-ahead-of-q3-earnings-4-takeaways-from-the-chart">Tesla Stock Faces Selling Pressure Ahead Of Q3 Earnings: 4 Takeaways From The Chart</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

PLTR

Jim Cramer's Bullish On Palantir, But Is The Stock's Winning Streak Too Hot?

DA Davidson analyst Gil Luria maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Buy and raises the price target from $285 to $315.

MANH

DA Davidson Maintains Buy on Manhattan Associates, Raises Price Target to $315

TD Cowen analyst Joseph Giordano maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Buy and raises the price target from $95 to $110.

TD Cowen Maintains Buy on Pentair, Raises Price Target to $110

We all knew that Intel ($INTC) has been on the ropes these days. But this chip stock is not taking the situation lying down. In fact, it is turning...

Intel (NASDAQ:INTC) and AMD Team-Up on New Project

How is QQQ stock faring? The Invesco QQQ ETF is up 0.03% in the past five days and has risen about 22.01% year-to-date.   According to TipRanks' un...

QQQ ETF Update, 10/16/2024

Arm Holdings: Decelerating Growth Prospects Question Its Extremely Expensive Valuations

How is QQQ stock faring? The Invesco QQQ ETF is up 0.94% in the past 5 days and has risen about 39.98% over the past year.   According to TipRanks'...

QQQ ETF Update, 10/21/2024

Micron, Qualcomm seen 'in limbo' going into earnings: Barclays

IFPI, representing the recording industry worldwide, has announced its support for the following AI Training Statement: The unlicensed use of creat...

IFPI supports AI Training Statement on unlicensed use of creative works

Arm to cancel chip design license deal with Qualcomm over contract dispute - report

JPMorgan says Bloomberg reported that Arm (ARM) is cancelling Qualcomm's (QCOM) architectural license by putting Qualcomm on a 60-day notice prior ...

JPMorgan sees Arm license cancelation as negotiation tactic versus Qualcomm

After Bloomberg reported that ARM Holdings (ARM) has given Qualcomm (QCOM) a mandated 60-day notice of cancellation of the licensing agreement that...

Citi see 'minimal impact' to Qualcomm, but possible drawn-out fight with Arm

Citi sees 'minimal impact' to Qualcomm, but possible drawn-out fight with Arm

AAPL

ABNB

AMZN

ASML

BIIB

BKNG

DXCM

FTNT

GOOG

GOOGL

INTC

LRCX

MRNA

MSFT

QCOM

SFTBF

SFTBY

Screenshot 2024-07-09 at 1.55.05 PM

Commodities

CSE:PURR

GLIOF

Panther Minerals (OTC: GLIOF) May Be Poised To Benefit Amid Nuclear Power Push For AI Data Center Growth

Press Releases

Vocodia Is Ushering In A New Era And Setting A High Benchmark For Conversational AI Technology ($VHAI)

Arm Holdings plc to Join the Nasdaq-100 Index® Beginning June 24, 2024

Small Cap

Opinion

Private Sector Pushes Forward Amid US-China AI Regulation Disputes

Arm Announces Earnings Release Date for First Quarter Fiscal Year Ended 2025

Arm Holdings plc Reports Results for the First Quarter of the Financial Year Ended 2025

Arm Announces Appointment of Young Sohn to its Board of Directors

Arm Joins the PHLX Semiconductor Sector Index℠ (SOX℠)

Arm Announces Earnings Release Date for Second Quarter Fiscal Year Ended 2025

AVAI

BIDU

NDAQ

NDXE

NDXESG

NDXSES

NDXT

NDXTMC

NDXX

NNOX

PEGA

SIRI

SOUN

TSLA

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

ASE Tech Holding Co

Broadcom

Cirrus Logic

First Solar

GLOBALFOUNDRIES

Intel

Lattice Semiconductor Corporation - Common Stock

Lattice Semiconductor

Microchip Technology Incorporated - Common Stock

Microchip Technology

Monolithic Power Systems, Inc. - Common Stock

Monolithic Power Systems

Marvell Tech

MACOM Technology Solutions Holdings, Inc. - Common Stock

MACOM Technology Solns

Micron Technology

NVIDIA

Universal Display Corporation - Common Stock

Universal Display

ON Semiconductor Corporation - Common Stock

ON Semiconductor

Qualcomm

Qorvo

STMicroelectronics

Skyworks Solutions

Taiwan Semiconductor Manufacturing Company Ltd.

Taiwan Semiconductor

Texas Instruments Incorporated - Common Stock

Texas Instruments

United Microelectronics Corporation (NEW) Common Stock

Comments

ARM Holdings

ARM Holdings (ARM) Options

ARM Holdings (NASDAQ:ARM) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL